Videos

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.

Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.

Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

Inavolisib plus palbociclib and fulvestrant reduced the risk of progression or death in HR+/HER2– PIK3CA-mutated advanced or metastatic breast cancer.

Anthracycline/taxane/cyclophosphamide was linked to improved RFS in MammaPrint high-2–risk, BluePrint Luminal B, HR-positive, HER2-negative breast cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

Tiffany A. Traina, MD, presents a patient case involving a woman diagnosed with HR-negative, HER2 3+ invasive ductal adenocarcinoma and elaborates on the clinical management approaches employed in her treatment sequencing.

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

Perioperative pembrolizumab plus chemotherapy improved survival vs preoperative chemotherapy in high-risk, early-stage, triple-negative breast cancer.

Ribociclib plus endocrine therapy bested combination chemotherapy in terms of progression-free survival in HR-positive, HER2-negative advanced breast cancer.

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.